List view / Grid view
19 November 2014 | By Boehringer Ingelheim
Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin...
19 November 2014 | By GlobalData
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData...
19 November 2014 | By Boehringer Ingelheim
New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism...
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
19 November 2014 | By The Tufts Center for the Study of Drug Development
Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...
19 November 2014 | By Forward Pharma A/S
Forward Pharma A/S announced that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera® in Germany...
19 November 2014 | By The Access to Medicine Index
The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years...
19 November 2014 | By Sanofi / Regeneron Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…
18 November 2014 | By Bioquell
Reducing infection transmission risk on a paediatric high dependency unit was just one of the topics under discussion at Lyon, France on the first day of the Healthcare Infection Society Conference 2014...
18 November 2014 | By Actavis
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Actavis has agreed to purchase Allergan for around $66 billion, in a deal which draws to an end Valeant’s lengthy wrangle to acquire the Botox manufacturer..."
18 November 2014 | By Public Health England
Four in ten people take antibiotics for a cough or runny nose despite both conditions normally clearing up without treatment, according to new research out by Public Health England (PHE) for European Antibiotic Awareness Day (EAAD)...
People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST...
18 November 2014 | By LNC
The results of the Obeminale program demonstrate the safety and efficacy of Stablor, with an average of 18% fat loss and 9% weight loss in overweight and obese people...
18 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT (Assessing Very Early Rheumatoid arthritis Treatment) trial that investigated the use of Orencia plus methotrexate (MTX) in biologic and MTX-naïve citrullinated protein (CCP)-positive early moderate to severe rheumatoid arthritis (RA) patients...
